DOI QR코드

DOI QR Code

The Effects of Rosiglitazone on in vivo Synthesis of Bone Collagen in Mice

Rosiglitazone이 마우스의 골조직 Collagen생성에 미치는 영향

  • Published : 2004.01.01

Abstract

This study was performed to investigate the effect of rosiglitazone, a new antidiabetic agent, on in vivo synthesis of bone collagen. The mice were divided into low-fat diet group (LF), high-fat diet group (HF), and high-fat diet with rosiglitazone (6.3 $\mu\textrm{g}$/kcal diet) group (HF-Rosi), The synthesis of bone collagen was measured by stable isotope-mass spectrometric technique using $^2$$H_2O$ as a tracer. The $^2$$H_2O$ labeling protocol consisted of an initial intraperitoneal injection of 99.9% $^2$$H_2O$, to achieve approximately 2.5% body water enrichment followed by administration of 4% $^2$$H_2O$ in drinking water for 3 weeks. Although body weight gain and daily diet intake were not significantly different between groups, HF-Rosi had slightly higher body weight gain and daily diet intake than LF and HF. In addition, HF-Rosi showed significantly higher body fat content than LF and HF. Bone collagen synthesis was reduced in HF than LF and further decreased by the treatment of rosiglitazone. These results suggest rosiglitazone affect body fat content and bone turnover in mice.

본 연구는 인술린비의존성 당뇨병환자의 경구용 혈당강하제로 사용되는 rosiglitazone이 in vivo 골조직 collagen의 신생율에 미치는 영향을 측정하기 위해 수행되었다. 저지방식이군과 고지방식이군은 각각 총열량의 10%와 45%를 지방으로 공급하였고 rosiglitazone 첨가군은 고지방식이에 rosiglitazone을 6.3 $\mu\textrm{g}$/kcal로 조절하여 공급하였다. 또한 collagen의 신생율을 안정동위원소비 질량분석법으로 측정하기 위하여 99.9% $^2$$H_2O$를 일시 복강주입하여 실험동물 체액의 $^2$$H_2O$ 수준을 2.0∼2.5%에 도달시킨 후 4% $^2$$H_2O$를 음용으로 3주 동안 계속 공급하였다. 체중증가량 및 식이섭취량은 각 실험군간에 유의한 차이가 없었으나 rosiglitazone첨가군이 다른 실험군에 비하여 높은 경향을 보였고, 체지방함량은 고지방식에 rosiglitazone를 첨가한 군이 다른 군에 비하여 유의한 증가를 보였다. 고지방식이군이 저지방식이군보다 골조직 collagen의 신생율이 낮았고 rosiglitazone의 첨가는 collagen의 신생율을 더욱 감소시켰으나 유의한 차이를 보이지는 않았다.

Keywords

References

  1. Pharmacogenomics v.3 Novel insulin sensitizers: pharmacogenomic aspects. Otto,C.;Lehrke,M.;Goke,B. https://doi.org/10.1517/14622416.3.1.99
  2. Life Sci v.67 Troglitazone and related compounds: therapeutic potential beyond diabetes Fujiwara,T.;Horikoshi,H. https://doi.org/10.1016/S0024-3205(00)00829-8
  3. Diabetologia v.45 Thiazolidinediones: metabolic actions in vitro Furnsinn,C.;Waldhausl,W. https://doi.org/10.1007/s00125-002-0899-1
  4. Metabolism v.50 Insulin-sensitizing effect of rosiglitazone (BRL 49653) by regulation of glucose transporters in muscle and fat of zucker rats Kramer,D.;Shapiro,R.;Adler,A.;Bush,E.;Rondinone,C.M. https://doi.org/10.1053/meta.2001.27202
  5. Diabetes v.47 A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metab olism in liver of Zucker fatty rats Murakami,K.;Tobe,K.;Ide,T.;Mochizuki,T.;Ohashi,M.;Akanuma,Y.;Yazaki,Y.;Kadowaki,T. https://doi.org/10.2337/diabetes.47.12.1841
  6. Mol Endocrinol v.16 A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity Rieusset,J.;Touri,F.;Michalik,L.;Escher,P.;Desvergne,B.;Niesor,E.;Wahli,W. https://doi.org/10.1210/me.2002-0036
  7. Diabetes Metab Res Rev v.18 no.Suppl.2 The mode of action of thiazolidinediones Hauner,H. https://doi.org/10.1002/dmrr.249
  8. Mutat Res v.448 Peroxisome proliferator activated receptors: insight into multiple cellular functions Escher,P.;Wahli,W. https://doi.org/10.1016/S0027-5107(99)00231-6
  9. The aging skeleton Cellular mechanisms of age related bone loss Robey,P.G.;Bianco,P.;Rosen,C.(ed.);Glowacki,J.(ed.);Bilezikian,J.P.(ed.)
  10. J Cell Biochem v.74 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR2 Lecka-Czernik B.;Gubrij,I.;Moerman,E.J.;Kajkenova,O.;Lipschitz,D.A.;Manolagas,S.C.;Jilka,R.L. https://doi.org/10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7
  11. Endocrinology v.140 Thiazolidinedione effects on glucocorticoid recept ormediated gene transcription and differentation in osteoblastic cells Johnson,T.E.;Vogel,R.;Rutledge,S.J.;Rodan,G.;Schmidt,A. https://doi.org/10.1210/en.140.7.3245
  12. Mol Pharmacol v.50 Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells Gimble,J.M.;Robinson,C.E.;Wu,X.;Kelly,K.A.;Rodriguez,B.R.;Kliewer,S.A.;Lehmann,J.M.;Morris,D.C.
  13. Endocrinology v.140 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro Okazaki,R.;Toriumi,M.;Fukumoto,S.;Miyamoto,M.;Fujita,T.;Tanaka,K.;Takeuchi,Y. https://doi.org/10.1210/en.140.11.5060
  14. Endocrinology v.143 Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation Lecka-Czernik B.;Moerman,E.J.;Grant,D.F.;Lehmann,J.M.;Manolagas,S.C.;Jilka,R.L. https://doi.org/10.1210/en.143.6.2376
  15. Endocrinology J v.46 Shortterm treatment with troglitazone decreases bone tumover in patients with type 2 diabetes mellitus Okazaki,R.;Miura,M.;Toriumi,M.;Taguchi,M.;Hirota,Y.;Fukumoto,S.;Fujita,T.;Tanaka,K.;Takeuchi,A.
  16. Metabolism v.49 Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243 Burkey,B.F.;Dong,M.;Gagen,K.;Eckhardt,M.;Dragonas,N.;Chen,W.;Grosenstein,P.;Argentieri,G.;de Souza,C.J. https://doi.org/10.1053/meta.2000.9524
  17. Diabetes v.50 Effects of pioglitzaone on adipose tissue remodeling within the setting of obesity and insulin resistance de Souza,C.J.;Eckhardt,M.;Gagen,K.;Dong,M.;Chen,W.;Laurent,D.;Burkey,B.F. https://doi.org/10.2337/diabetes.50.8.1863
  18. Mol Cell v.4 PPAR-γ is required for placental, cardiac, and adipose tissue development Barak,Y.;Nelson,M.C.;Ong,E.S.;Jones,Y.Z.;Ruiz-Lozano P.;Chien,K.R.;Koder,A.;Evans,R.M. https://doi.org/10.1016/S1097-2765(00)80209-9
  19. Mol Cell v.4 PPAR-γ is required for the differentiation of adipose tissue in vivo and in vitro Rosen,E.D.;Sarraf,P.;Troy,A.E.;Bradwin,G.;Moore,K.;Milstone,D.S.;Spiegelman,B.M.;Mortensen,R.M. https://doi.org/10.1016/S1097-2765(00)80211-7
  20. Diabetes v.46 Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat Hallakou,S.;Doare,L.;Foufelle,F.;Kergoat,M.;Guerre-Millo M.;Berthault,M.F.;Dugail,I.;Morin,J.;Auwerx,J.;Ferre,P. https://doi.org/10.2337/diabetes.46.9.1393
  21. J Clin Invest v.98 Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor De Vos,P.;Lefebvre,A.M.;Miller,S.G.;Guerre-Millo M.;Wong,K.;Saladin,R.;Hamann,L.G.;Staels,B.;Briggs,M.R.;Auwerx,J. https://doi.org/10.1172/JCI118860
  22. N Engl J Med v.338 Effect of troglitazone in insulin-treated patients with type II diabetes mellitus Schwartz,S.;Raskin,P.;Fonseca,V.;Graveline,J.F. https://doi.org/10.1056/NEJM199803263381302